Epidemiology and Treatment Patterns of Stage III Resectable Melanoma Treated with Adjuvant Therapy: A Real-World Study Using the SNDS Database in France - Summary - MDSpire

Epidemiology and Treatment Patterns of Stage III Resectable Melanoma Treated with Adjuvant Therapy: A Real-World Study Using the SNDS Database in France

  • By

  • Sandrine Monestier

  • Sebastien Branchoux

  • Louis Chillotti

  • François-Emery Cotté

  • Clémentine Curioz

  • Mélanie Goguillot

  • Stève Bénard

  • Carine Bellera

  • Nicolas Meyer

  • June 8, 2026

  • 0 min

Share

Objective:

To describe treatment patterns and survival outcomes in patients with stage III resectable melanoma treated with adjuvant therapy in France.

Key Findings:
  • Among 2612 patients, 36-month overall survival (OS) was approximately 80%.
  • 36-month recurrence-free survival (RFS) was around 50%.
  • Immunotherapy constituted 70% of adjuvant therapies and 75% of recurrence therapies.
Interpretation:

The study provides real-world evidence on treatment patterns and survival outcomes in stage III melanoma.

Limitations:
  • The study relies on claims data, which may have limitations in accuracy and completeness.
  • Findings may not be generalizable beyond the French healthcare system.
Conclusion:

The study provides insights into treatment patterns and outcomes in stage III melanoma.

Original Source(s)

Epidemiology and Treatment Patterns of Stage III Resectable Melanoma Treated with Adjuvant Therapy: A Real-World Study Using the SNDS Database in France

  • by Sandrine Monestier, Sebastien Branchoux, Louis Chillotti, François-Emery Cotté, Clémentine Curioz, Mélanie Goguillot, Stève Bénard, Carine Bellera, Nicolas Meyer

  • June 8, 2026

Related Content

Dual concatenated transfer learning with attention fusion: An ensemble-enhanced approach for skin lesion classification

Withdrawal of Correction: Chamaejasmin B Reduces Malignant Traits in Mouse Melanoma B16F0 and B16F10 Cell Lines

  • April 27, 2026

Retrospective Study of Immunoembolization for Liver-Dominant Metastatic Uveal Melanoma at a Single Institution